| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.52.8.1673 |
| P8608 | Fatcat ID | release_ljolskd5pja7roerephsrkvi2i |
| P698 | PubMed publication ID | 10331698 |
| P2093 | author name string | Mori A | |
| Bédard PJ | |||
| Grégoire L | |||
| Hadj Tahar A | |||
| Kase H | |||
| Grondin R | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1673-1677 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys | |
| P478 | volume | 52 |
| Q34365007 | 3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects |
| Q36057652 | A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease |
| Q44668510 | A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease |
| Q92583755 | Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease |
| Q24201502 | Adenosine A 2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease |
| Q28362843 | Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus |
| Q64771861 | Adenosine A(2A) receptor mRNA expression in Parkinson's disease |
| Q36973390 | Adenosine A(2A) receptors in Parkinson's disease treatment |
| Q30482913 | Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition |
| Q44865042 | Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease |
| Q29346492 | Adenosine A2A Receptor Antagonists and Parkinson’s Disease |
| Q44175279 | Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats |
| Q35592790 | Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease |
| Q37348458 | Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease |
| Q46733333 | Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. |
| Q36172464 | Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience |
| Q38200930 | Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued |
| Q35917127 | Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum |
| Q24676705 | Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain |
| Q36083482 | Adenosine and brain function |
| Q40657295 | Adenosine as a neuroprotectant: therapeutic perspectives |
| Q33955930 | Adenosine in the central nervous system: release mechanisms and extracellular concentrations |
| Q28593583 | Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice |
| Q35172268 | Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. |
| Q37818990 | Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration |
| Q35063214 | Adenosine receptors in the nervous system: pathophysiological implications. |
| Q57708611 | Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease |
| Q44674177 | Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. |
| Q38602173 | Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets. |
| Q44760113 | Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. |
| Q47447585 | CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors |
| Q42481890 | CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats |
| Q73302947 | Central adenosine A(2A) receptors: an overview |
| Q44658244 | Characterization of the rat A2A adenosine receptor gene: a 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system |
| Q43959920 | Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. |
| Q37680038 | Disease-Specific Heteromerization of G-Protein-Coupled Receptors That Target Drugs of Abuse |
| Q40367305 | Distinctive and synergistic signaling of human adenosine A2a and dopamine D2L receptors in CHO cells |
| Q37358676 | Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease |
| Q48020769 | Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects |
| Q38237288 | Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials |
| Q51364017 | Evaluation of the Effects of a High‐Fat Meal on the Oral Bioavailability of a Single Dose of Preladenant in Healthy Subjects |
| Q48326584 | Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. |
| Q82029286 | Functional neurochemistry of the basal ganglia |
| Q37950428 | Future Treatments for Parkinson's Disease: Surfing the PD Pipeline |
| Q42445750 | Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. |
| Q90047541 | In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385 |
| Q52665081 | In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease. |
| Q45711922 | Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias |
| Q44356897 | Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists |
| Q42135362 | Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. |
| Q37965615 | Istradefylline for the treatment of Parkinson's disease |
| Q44360692 | Istradefylline: First Global Approval |
| Q42800140 | Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats |
| Q34802076 | MPTP: insights into parkinsonian neurodegeneration |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q46087825 | Metabotropic glutamate receptor II in the brains of Parkinsonian patients |
| Q44050773 | Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. |
| Q60643597 | Modulation by adenosine A2A receptors of dopamine-mediated motor behavior as a basis for antiparkinson?s disease drugs |
| Q48111297 | Modulation of inhibitory transmission in the rat globus pallidus by activation of mGluR4. |
| Q28210110 | Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats |
| Q24604052 | Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease |
| Q42480222 | Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. |
| Q48109639 | Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease |
| Q47267653 | Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease |
| Q37974709 | New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors |
| Q36188913 | Nondopaminergic mechanisms in levodopa-induced dyskinesia |
| Q37824017 | Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies |
| Q37627259 | Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. |
| Q36610996 | Novel pharmacological targets for the treatment of Parkinson's disease |
| Q37844573 | Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. |
| Q35614156 | Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa |
| Q35489240 | Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. |
| Q43875632 | Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. |
| Q26852311 | Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates |
| Q46529369 | Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain |
| Q87262241 | Potent, Metabolically Stable 2-Alkyl-8-(2H-1,2,3-triazol-2-yl)-9H-adenines as Adenosine A2A Receptor Ligands |
| Q34777609 | Preclinical jockeying on the translational track of adenosine A2A receptors |
| Q43263782 | Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus |
| Q37264464 | Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities |
| Q34532735 | Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors |
| Q35545074 | Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships |
| Q64086268 | Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling |
| Q40647461 | Recent developments in the field of A2A and A3 adenosine receptor antagonists |
| Q64901815 | Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. |
| Q64868285 | Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist |
| Q48112379 | Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia |
| Q51355872 | Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects |
| Q44506257 | Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats |
| Q28188402 | Selective adenosine A2A receptor antagonists |
| Q51406538 | Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors |
| Q44811440 | Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. |
| Q34070904 | Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism |
| Q46334842 | Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations |
| Q38103966 | Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations |
| Q47137101 | Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches |
| Q35105740 | The Fluctuating Parkinsonian Patient - Clinical and Pathophysiological Aspects |
| Q37796015 | The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future |
| Q32065404 | The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia |
| Q46848335 | The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. |
| Q46506816 | The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates |
| Q56700734 | The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat |
| Q28293887 | The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat |
| Q44464146 | The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. |
| Q38353204 | The safety of istradefylline for the treatment of Parkinson's disease |
| Q26991826 | Therapy for Parkinson's disease: what is in the pipeline? |
| Q36249210 | Treatment of Parkinson's disease : what's on the horizon? |
| Q44830958 | Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. |
| Q38660240 | mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias |
Search more.